Autopsy report · NCT04407442

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

“Slow enrollment and change in sponsor direction”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 2 years 5 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of California, San Francisco

Sponsor type

University, hospital or other

Conditions

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma

Interventions

Azacitidine; Daratumumab; Dexamethasone

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
  “Sponsor stopped due to slow enrollment” (85% match in meaning)
• Noninvasive Neurostimulation of the Vagus Nerve for the Relief of Acute Bronchoconstriction Due to Asthma
  “Slow enrollment” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.